Valuation: Patrys Limited

Market Cap 2.33Cr 1.66Cr 1.42Cr 1.33Cr 1.22Cr 2.29Cr 158.95Cr 16Cr 6.14Cr 80Cr 6.24Cr 6.1Cr 263.73Cr P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 2.26Cr 1.61Cr 1.38Cr 1.28Cr 1.18Cr 2.22Cr 153.89Cr 15Cr 5.94Cr 77Cr 6.04Cr 5.91Cr 255.33Cr EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 week+6.45%
1 month-8.33%
3 months-8.33%
6 months-2.94%
Current year+17.86%
1 week 0.03
Extreme 0.032
0.03
1 month 0.03
Extreme 0.031
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap.
11/08/23 Expiration

Chief Executive Officer

3,96,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

13,37,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+6.45%+120.01%-69.44% 1.57Cr
+2.38%+3.43%+82.88%+115.89% 7.4TCr
-0.29%+20.73%+53.06%+93.29% 6.47TCr
-4.27%-0.99%-3.38%+475.61% 2.73TCr
-1.97%+20.38%-0.37%+0.48% 2.79TCr
+2.44%+12.43%+62.04%+27.51% 2.6TCr
-0.21%+5.73%+38.71%-12.79% 2TCr
-1.79%-4.84%+239.54%+414.48% 1.78TCr
+1.22%+3.75%+19.00%+535.29% 1.62TCr
-1.29%+6.09%+41.81%+154.45% 1.33TCr
Average -0.40%+5.88%+65.33%+173.48% 2.87TCr
Weighted average by Cap. +0.01%+8.21%+59.14%+160.93%

Financials

2024 2025
Net sales 13.94L 10L 8L 8L 7L 13.67L 9.5Cr 94.07L 36.67L 4.76Cr 37.27L 36.46L 16Cr 8L 6L 5L 5L 4L 8L 5.64Cr 55.91L 21.79L 2.83Cr 22.15L 21.67L 9.37Cr
Net income -35.39L -25.2L -21.58L -20.13L -18.47L -34.71L -24Cr -2.39Cr -93.09L -12Cr -94.62L -92.56L -40Cr -30.13L -21.45L -18.37L -17.14L -15.73L -29.55L -21Cr -2.03Cr -79.26L -10Cr -80.56L -78.81L -34Cr
Net Debt -22.41L -15.95L -13.66L -12.74L -11.69L -21.97L -15Cr -1.51Cr -58.94L -7.65Cr -59.9L -58.6L -25Cr -7L -5L -5L -4L -4L -7L -5.06Cr -50.1L -19.53L -2.53Cr -19.85L -19.42L -8.39Cr
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
21/26/21 A$0.0330 0.00% 250
20/26/20 A$0.0330 +3.13% 2,38,219
19/26/19 A$0.0320 0.00% 3,374
18/26/18 A$0.0320 0.00% 1
17/26/17 A$0.0320 +3.23% 59,046